Muller & Phipps (India) Limited is a Mumbai-based marketing and distribution enterprise specializing in the **FMCG and healthcare** sectors. The company operates a brand-management-centric business model, focusing on the commercialization of proprietary **Over-the-Counter (OTC) medical preparations**, **personal care**, and **home care** products. With a legacy presence in the Indian market, the company is currently navigating a strategic transition aimed at financial recovery and portfolio diversification. --- ### **Core Product Portfolio & Brand Assets** The company’s revenue is primarily driven by established brands in the dental and skincare categories. The business model emphasizes brand management and distribution rather than direct manufacturing. * **Dental Care:** * **Cavisan:** A specialized dental formulation brand. * **Cavidine:** Antiseptic and medicated dental solutions. * **Skin Care:** * **Nixoderm:** A legacy brand focused on the treatment of skin irritations and various dermatological conditions. * **Home Care & OTC:** General marketing of medical preparations and home care solutions. * **Historical Segments:** The company previously operated in the frozen foods category under the **Tiff-n-Bite** and **Treatos** brands (noted in 2023 records). --- ### **Pan-India Distribution & Operational Infrastructure** The company maintains a robust national footprint through a network of regional offices and depots, ensuring product availability across diverse geographic zones: | Region | Key Locations / Depots | | :--- | :--- | | **West** | Mumbai (Headquarters), Indore | | **North** | Delhi, Ghaziabad, Chandigarh | | **East** | Kolkata, Patna | | **South** | Kochi | *Note: The Raipur depot, active in 2023, was not explicitly cited in 2024-25 operational documentation.* --- ### **Corporate Structure & Strategic Affiliations** Muller & Phipps (India) Limited is a subsidiary of **Development Holding Asia Ltd.**, which maintains a significant stake of **3,22,680 equity shares**. The company’s ecosystem includes several subsidiaries and associates: | Entity | Relationship | Business Activity | | :--- | :--- | :--- | | **Muller & Phipps (Industrial Services) Ltd.** | Subsidiary | Indenting Agents in India | | **Muller & Phipps Agencies Ltd.** | Subsidiary | No business activity since inception | | **Getz Bros. Company Limited** | Fellow Subsidiary | N/A | | **Foods and Inns Ltd.** | Associate | N/A | | **Getz Pharma Pvt. Ltd.** | Associate | N/A | | **Western Press Pvt Ltd.** | Associate | N/A | --- ### **Financial Performance & Solvency Analysis** The company’s financial profile is characterized by a recovery trend despite a historical deficit. While the **net worth remains eroded**, management has maintained **Going Concern** status based on recent profitability and future growth projections. **Key Financial Metrics (Standalone & Consolidated):** | Metric | Dec 31, 2025 | Sept 30, 2025 | Mar 31, 2025 | Mar 31, 2024 | | :--- | :--- | :--- | :--- | :--- | | **Accumulated Losses** | **₹2.45 crore** | **₹2.05 crore** | **₹4.92 crore** | **₹4.17 crore** | | **Net Worth** | **(₹1.82 crore)** | **(₹1.43 crore)** | **(₹2.08 crore)** | **(₹1.31 crore)** | **Earnings Highlights (FY 2023-24):** * **Profit After Tax (Consolidated):** **₹72.81 lakhs** (up from **₹21.23 lakhs** in FY23). * **Earnings Per Share (EPS):** Increased significantly to **₹11.65** from **₹3.4**. * **Exceptional Items:** FY24 results were bolstered by compensation received for the **surrender of tenancy rights** at the **Kolkata** location. * **Core Profitability:** Profit Before Exceptional Items stood at **₹32.98 lakhs** (Standalone). --- ### **Strategic Growth & Governance Roadmap** Management is focused on institutional stability and portfolio expansion to offset carried-forward losses. * **Portfolio Broad-basing:** Active efforts are underway to acquire or market **additional products** to increase turnover and leverage the existing distribution network. * **Governance Enhancements:** * **Board Diversity:** Appointment of **Mrs. Hinal Shah** as a **Woman Independent Director** for a **5-year term** (effective **2025 AGM**). * **Audit Oversight:** Engagement of **Sanjay Soman & Associates** as **Secretarial Auditors** for a fixed tenure from **FY 2025-26 to FY 2029-30**. * **Capital Allocation:** Due to the necessity of adjusting profits against **carried forward losses**, the company has recommended **Nil dividends** and **Nil transfer to reserves** for the recent cycles. The capital structure remains simple, with equity shares at a **par value of ₹10**. --- ### **Risk Profile & Mitigation Factors** Investors should note the following risks inherent in the company’s current operational and financial state: * **Client Concentration:** Revenue is highly sensitive to a small group of customers. * **Revenue from Top 10 Clients:** Increased to **75%** in FY24 from **60%** in FY23. * **Credit & Liquidity Risk:** Most transactions are conducted on **credit**, exposing the company to **accounts receivable** defaults. The negative net worth necessitates careful liquidity management to fund strategic investments. * **Macroeconomic Sensitivity:** Operations are vulnerable to **inflationary pressures** and **input cost escalations**, which can impact consumer purchasing power when passed through via price revisions. * **Valuation Risks:** The company holds **Level 3 Financial Instruments**, where fair value is determined using non-observable market data, introducing potential estimation errors. * **Regulatory Compliance:** The company operates under strict adherence to **Sections 149, 152, and 204** of the **Companies Act, 2013**, and **Regulation 24A** of **SEBI (LODR) Regulations, 2015**.